| 臺大學術典藏 |
2022-02-21T03:52:37Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 臺大學術典藏 |
2022-01-14T03:59:36Z |
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
|
Ahn M.-J.; D'Cruz A.; Vermorken J.B.; JO-PAI CHEN; Chitapanarux I.; Dang H.Q.T.; Guminski A.; Kannarunimit D.; Lin T.-Y.; Ng W.T.; Park K.-U.; Chan A.T.C. |
| 國立成功大學 |
2022 |
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
|
Wu, Y.-L.;Lu, S.;Yang, J.C.-H.;Zhou, J.;Seto, T.;Ahn, M.-J.;Su, W.-C.;Yamamoto, N.;Kim, D.-W.;Paolini, J.;Usari, T.;Iadeluca, L.;Wilner, K.D.;Goto, K. |
| 臺大學術典藏 |
2021-07-13T06:04:35Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; LEE JIH-HSIANG; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 臺大學術典藏 |
2021-04-23T05:56:33Z |
Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies
|
Ahn M.-J.;Han J.-Y.;Kim D.-W.;Cho B.C.;Kang J.-H.;Kim S.-W.;Chih-Hsin Yang;Mitsudomi T.;Lee J.S.; Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG; Mitsudomi T.; Lee J.S. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
|
Chih-Hsin Yang;Kim S.-W.;Kim D.-W.;Lee J.-S.;Cho B.C.;Ahn J.-S.;Lee D.H.;Kim T.M.;Goldman J.W.;Natale R.B.;Brown A.P.;Collins B.;Chmielecki J.;Vishwanathan K.;Mendoza-Naranjo A.;Ahn M.-J.; CHIH-HSIN YANG; Kim S.-W.; Kim D.-W.; Lee J.-S.; Cho B.C.; Ahn J.-S.; Lee D.H.; Kim T.M.; Goldman J.W.; Natale R.B.; Brown A.P.; Collins B.; Chmielecki J.; Vishwanathan K.; Mendoza-Naranjo A.; Ahn M.-J. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.;Chua K.L.M.;Lin C.-C.;Lee V.H.F.;Tho L.M.;Chan A.W.;Ho G.F.;Reungwetwattana T.;Ychih-Hsin Yang;Kim D.-W.;Soo R.A.;Ahn Y.C.;Onishi H.;Ahn M.-J.;Mok T.S.K.;Tan D.S.W.;Yang F.; Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2021-04-23T05:56:30Z |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|
Oxnard G.R.;Chih-Hsin Yang;Yu H.;Kim S.-W.;Saka H.;Horn L.;Goto K.;Ohe Y.;Mann H.;Thress K.S.;Frigault M.M.;Vishwanathan K.;Ghiorghiu D.;Ramalingam S.S.;Ahn M.-J.; Oxnard G.R.; CHIH-HSIN YANG; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor�VNaive ALK-Positive Non�VSmall Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
|
Camidge D.R.;Kim H.R.;Ahn M.-J.;Chih-Hsin Yang;Han J.-Y.;Hochmair M.J.;Lee K.H.;Delmonte A.;Garc?A Campelo M.R.;Kim D.-W.;Griesinger F.;Felip E.;Califano R.;Spira A.;Gettinger S.N.;Tiseo M.;Lin H.M.;Gupta N.;Hanley M.J.;Ni Q.;Zhang P.;Popat S.; Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:27:06Z |
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
|
Orlando M.;Linn C;Peng G;Blair J.M;Chen Y.-M;Xiu Q;Kang J.-H;Liang J;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Liang J; Kang J.-H; Xiu Q; Chen Y.-M; Blair J.M; Peng G; Linn C; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:27:06Z |
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
|
Orlando M.;Linn C;Peng G;Blair J.M;Chen Y.-M;Xiu Q;Kang J.-H;Liang J;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Liang J; Kang J.-H; Xiu Q; Chen Y.-M; Blair J.M; Peng G; Linn C; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial
|
CHIH-HSIN YANG; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K.; Mok T.S.K.;Jiang H;Webster A;Shi X;Zhou J.-Y;Yoh K;Liu Y;Lee D.H;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Chih-Hsin Yang;Kim S.-W;Nakagawa K;Wu Y.-L;Soria J.-C; Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial
|
CHIH-HSIN YANG; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K.; Mok T.S.K.;Jiang H;Webster A;Shi X;Zhou J.-Y;Yoh K;Liu Y;Lee D.H;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Chih-Hsin Yang;Kim S.-W;Nakagawa K;Wu Y.-L;Soria J.-C; Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
|
Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
|
Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T. |
